Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Neurocrine Biosciences (NBIX)

Neurocrine completes $2.9 billion Soleno Therapeutics acquisition

Neutral Impact 4 of 5 m&a Written later

Neurocrine Biosciences completed its acquisition of Soleno Therapeutics on May 18, 2026, through a $53.00 per share cash tender offer and merger. The deal adds VYKAT XR, a treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's commercial portfolio. The company funded the roughly $2.9 billion cash payment from cash on hand and also drew $600.0 million under a new $1.0 billion revolving credit facility.

Key points

  • Tender offer price of $53.00 per share in cash; 46,356,114 Soleno shares, about 88.9% of outstanding shares, were validly tendered by the May 15, 2026 expiration
  • Aggregate cash paid was approximately $2.9 billion plus fees and expenses, funded from Neurocrine's available cash on hand
  • New five-year, $1.0 billion senior secured revolving credit facility with JPMorgan Chase Bank, N.A. dated May 14, 2026; $600.0 million initial borrowing made on that date
  • Soleno common stock will no longer be listed or traded on the Nasdaq Capital Market as of May 18, 2026

The filing

CompanyNeurocrine Biosciences (NBIX)
Form8-K, current report
Filed with the SECMay 18, 2026, 9:04 AM ET
Accession number0001193125-26-228013

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed2.03 New Direct Financial Obligation7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.